Physician profile
Jared Stephen Sharp
NPI 1306365507
$1,068.84
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $274 · 2024: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045 · Education: $23.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.22 |
| Education | $23.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $187.05 | 2024 | Stelara |
| E.R. Squibb & Sons, L.L.C. | $178.85 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.89 | 2023-2024 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $65.01 | 2023-2024 | Entyvio |
| Ardelyx, INC. | $58.65 | 2023-2024 | Ibsrela |
| Celltrion USA INC. | $55.04 | 2024 | Zymfentra |
| Abbvie INC. | $51.63 | 2024 | |
| Braintree Laboratories, INC. | $47.07 | 2024 | Suflave |
| Lilly USA, LLC | $44.77 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $43.43 | 2024 | Voquezna |
| Celgene Corporation | $39.29 | 2023-2024 | Zeposia |
| Genzyme Corporation | $38.21 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $37.61 | 2024 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.53 | 2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $24.74 | 2023 | Ocaliva |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.12 | 2023 | |
| Ferring Pharmaceuticals INC. | $21.54 | 2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $17.41 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.